IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression - Quiz - MDSpire

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

  • By

  • Alexandre Pérez-González

  • Jacobo Alonso-Domínguez

  • Inés Martínez-Barros

  • Aida López-López

  • Laura Labajo-Leal

  • Antonio Ocampo

  • Eva Poveda

  • May 28, 2026

  • 0 min

Share

Original Source(s)

IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression

  • by Alexandre Pérez-González, Jacobo Alonso-Domínguez, Inés Martínez-Barros, Aida López-López, Laura Labajo-Leal, Antonio Ocampo, Eva Poveda

  • May 28, 2026

Related Content

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

HHS Unveils Sweeping Plan to Combat Lyme Disease and Advance Treatment

Autophagy–ferroptosis crosstalk in sepsis: metabolic pathways, redox injury, and host-directed antioxidant nanomedicine